Gefapixant Tablets (Lifnua) is a selective P2X3 receptor antagonist indicated for the treatment of refractory chronic cough. It has been marketed in Japan since April 2022. As a prescription drug, its purchase and use must strictly comply with medical regulations.
What are the Purchase Channels for Gefapixant Tablets (Lifnua)?
Overseas Purchase
Patients may consult and purchase gefapixant tablets at hospital pharmacies or legitimate drugstores in countries/regions where the medication is marketed.
Since drug prices may be affected by regional differences, exchange rate fluctuations, and other factors, patients should make a budget and plan in advance before purchasing.
Purchase Through Medical Service Institutions
Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and offer professional consultation and guidance.
Precautions for Gefapixant Tablets (Lifnua)
Strictly Follow Doctor's Instructions
Gefapixant tablets are symptomatic treatment, not etiological treatment, and therefore should not be used blindly for a long period.
Patients can only use the medication after being evaluated by a doctor and confirmed to meet the indications.
Pay Attention to Contraindications and Side Effects
Contraindicated populations: Patients with hypersensitivity to any component of this product are prohibited from using it.
Common side effects: Taste disorders (such as dysgeusia, ageusia, etc.) have a high incidence, occurring in approximately 63.1% of patients. Others include nausea, upper respiratory tract infection, decreased appetite, etc.
Special populations: Dose adjustment is required for patients with severe renal impairment. Caution should be exercised when using this product in pregnant women, lactating women, and individuals under 18 years of age.
Verify Medication Information
When purchasing, check the medication name, active ingredient (gefapixant citrate), specification (45mg), batch number, expiration date, and other information to ensure consistency with the prescription.
Authentication of Gefapixant Tablets (Lifnua) Authenticity
Outer Packaging Identification
Trade name and logo: The genuine packaging should clearly print "リフヌア ® 錠 45mg" (Lifnua Tablets 45mg).
Approval number: The Japanese drug approval number is "30400AMX00008000", which can be verified on the packaging.
PTP packaging: Regular products adopt PTP blister packaging with the identification code "777".
Tablet Appearance
Shape and color: Genuine tablets are round, pink, film-coated, with a diameter of approximately 10.4mm and a thickness of approximately 5.3mm.
Identification code: The tablet is engraved with the code "777" for identification.
Scanning and Inquiry
Some medication packages are attached with a QR code or anti-counterfeiting label, which can be scanned to verify authenticity through the official App or website.
If the packaging is blurred, the code is unclear, or it is inconsistent with the official description, the product should be highly suspected of being counterfeit.
